Filing Analysis
Officer Departure
Filed Apr 22, 2026
MEDIUM
Tenax Therapeutics has appointed Thomas R. Staab, II as Chief Financial Officer, effective May 11, 2026, replacing interim CFO Thomas A. McGauley. Mr. Staab brings extensive executive experience from BioCryst Pharmaceuticals and LENSAR, and his compensation package includes significant equity inducements.
Key Facts
- Thomas R. Staab, II appointed as CFO effective May 11, 2026.
- Interim CFO Thomas A. McGauley will resign effective May 10, 2026, but will remain as principal financial officer through the filing of the Q1 2026 Form 10-Q.
- Mr. Staab's compensation includes an annual base salary of $428,000 and a 45% target bonus.
- Inducement equity awards consist of 10,000 restricted stock units (RSUs) and options to purchase 450,000 shares of common stock.
- Mr. Staab previously served as CFO of LENSAR, Inc. (NASDAQ: LNSR) and BioCryst Pharmaceuticals (NASDAQ: BCRX).
Regulation FD Disclosure
Filed Mar 10, 2026
LOW
Tenax Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025. The disclosure was made via a press release on March 10, 2026, and filed under Item 2.02.
Key Facts
- Financial results cover the fourth quarter and full year ended December 31, 2025.
- The report was filed on March 10, 2026.
- The filing includes Exhibit 99.1, which is the press release containing the detailed financial results.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.